Appunti VERIFICATO
antibiotico terapia
77 visualizzazioni
17 download
Nessun voto ancora
Stai vedendo l'anteprima delle prime pagine. Il file completo è gratis: registrati per leggerlo tutto.
Di cosa parla
- Evolution of Clinical Practice: The shift from a unitary disease concept to multi-morbidity in clinical medicine, highlighting the importance of evidence-based guidelines.
- Antibiotic Resistance Mechanisms: Discusses the definition of resistance levels (Not MDR, MDR, XDR, PDR), natural selection, human-mediated spread, food-borne and environmental contamination.
- Major Antibiotic Classes and Resistance: Details resistance mechanisms for Beta-lactams, Glycopeptides, Aminoglycosides, Macrolides, and Quinolones, emphasizing efflux pumps.
- Adaptive Resistance Development: Explores how bacteria develop resistance due to factors like concentration gradients, sub-inhibitory concentrations, epigenetic changes, and biofilm formation, and the potential for resistance reversibility.
- Specific Resistant Pathogens:
- Staphylococcus aureus (MRSA): Addresses the increasing vancomycin MIC and strategies like daptomycin for higher MICs. Notes the impact of fluoroquinolone restriction on MRSA prevalence.
- Vancomycin-Resistant Enterococci (VRE): Focuses on E. faecalis and E. faecium, intrinsic resistance, and the necessity of combination therapy (e.g., ampicillin + aminoglycoside).
- Carbapenem-Resistant Klebsiella pneumoniae (CR-KP): A significant nosocomial issue requiring high-dose, multi-drug combination therapy (e.g., carbapenem + colistin/tigecycline), with treatment guided by MIC values and infection site.
- Acinetobacter baumannii: Discusses high mortality risk for carriers and the use of localized colistin for improved chemosusceptibility.
- Clostridium difficile: Prevention strategies include appropriate antibiotic use, PPI reduction, and screening.
- Streptococcus pneumoniae: A common agent for community-acquired pneumonia, with rising macrolide resistance. Vaccination (PCV-13, PPSV-23) is a key preventive measure.
- Diagnosis and Prognosis: Differentiates pseudo-resistance from true resistance. Emphasizes that clinical assessment is crucial due to limitations of sepsis biomarkers. Highlights the prognostic significance of carbapenem resistance, linked to higher mortality.
- Prevention Strategies: Outlines comprehensive strategies including antibiotic stewardship (appropriate use, dose, time), personal and environmental hygiene, MRSA decolonization, vaccination, infection control measures for VAP, and exploring antibiotic adjuvants.
- Monitoring Treatment: Provides a timeline for evaluating antibiotic response (e.g., hypotension resolution in 2 days, fever in 3 days, CRP reduction in 4 days) and suggests a minimum of 8 days of therapy.
Questo appunto è gratis. Registrati in 30 secondi per leggere tutte le pagine e scaricarlo.